Bizarre Patents
A method of swing on a swing is disclosed, in which a user positioned on a standard swing suspended by two chains from a substantially horizontal tree branch induces side to side motion by pulling alternately on one chain and then the other.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7442720 | Compositions and methods for treating diabetes The subject invention provides compositions and methods for treating diabetes in patients. In a preferred embodiment, the invention provides compositions methods for treating diabetes and/or preventing or alleviating complications associated with diabetes. Specifica... | 10/28/2008 |
| 7442796 | Compounds for the treatment of metabolic disorders Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 0 to 4; ... | 10/28/2008 |
| 7427619 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy Pharmaceutical compositions effective in alleviating or reducing the effects of fatigue and weakness associated with cancer and cancer chemotherapy are disclosed. The pharmaceutical compositions of the present invention comprise riboflavin, effectors of the urea cyc... | 09/23/2008 |
| 7425577 | Lipase-colipase inhibitor The present invention relates to novel colipase-lipase inhibitors of the general formulae to be used in the treatment of prophylaxis of obesity, as well as pharmaceutical compositions containing the same, and method for treating obesity using said compounds. ... | 09/16/2008 |
| 7414044 | Use of targeted oxidative therapeutic formulation in treatment of type 2 diabetes A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as d... | 08/19/2008 |
| 7390504 | HDL-boosting combination therapy complexes A pharmaceutical composition including therapeutically effective amounts of at least one HMG-CoA reductase inhibitor present as a dyhydroxyacid salt and at least one additional therapeutic agent. ... | 06/24/2008 |
| 7378437 | Drugs for diabetes Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B)b0—(C)c0—NO2 wherein A contains the radical of a drug having an antiinflammatory or analgesic activity, B is a bivalent ... | 05/27/2008 |
| 7371764 | Quinolin-isoquinolin-and quinazolin-oxyalkylamides and their use as fungicides The present invention discloses fungicidal compounds and compositions of the formula (1): wherein the substituents R1, R2, R3, R4, R5, X, Y and Z are as defined in the ... | 05/13/2008 |
| 7361690 | Compositions and methods for the treatment of urinary incontinence A method for treating increased uninary urgency or urinary incontinence, comprising administering an effective amount of a compound corresponding to formula I It has been surprisingly discovered that the methods of the pres... | 04/22/2008 |
| 7326695 | Anti-bacterial agents based upon oxoanion binding Compounds of the structure I: are useful for treating bacterial growth, wherein E is selected from the group consisting of B, P, and S, T1 and T2 are each independen... | 02/05/2008 |
| RE40000 | Method of treatment for decreasing mortality resulting from congestive heart failure A method of treatment using a compound of Formula I: wherein: R1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl; R | 01/08/2008 |
| 7157499 | Medical application of oxidized monoterpenes Preferred compositions used to inhibit the growth of bacteria, fungi and yeast include perillyl aldehyde as an active ingredient. Other active ingredients include perillyl alcohol. The compositions are formed as gels, creams, liquids and dry formulations. ... | 01/02/2007 |
| 7122577 | Composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the treatment and diagnosis of disease A composition including a purified lipid cell-wall component or analog or derivative thereof and a suitable pharmaceutical carrier, medium, excipient or adjuvant is described. The composition is useful in prophylactic and therapeutic methods of treating a microbial ... | 10/17/2006 |
| 7105529 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, ... | 09/12/2006 |
| 7084157 | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation The present invention relates to novel ophthalmic pharmaceutical compositions comprising an inflammation-treating amount of a 4-aminoquinoline compound, derivative, isomers, or chemical salts, and methods for using these compositions for the treatment of ocular infl... | 08/01/2006 |
| 7074776 | Anti-bacterial agents based upon oxoanion binding Compounds of the structure I: are useful for treating bacterial growth, wherein E is selected from the group consisting of B, P, and S, T1 and T2 are each independen... | 07/11/2006 |
| 7064130 | Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders A method of treatment of the human or non-human animal body for treating NO-dependent microcirculation disorders is disclosed, for example microcirculation disorders caused by metabolic diseases, such as elevated levels of homocystin-homocystein inflammatory reactio... | 06/20/2006 |
| 7053116 | Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production In accordance with the present invention, there are provided novel methods of blocking amyloid protein toxicity in cells using polycylic compounds. Also provided are novel methods of decreasing amyloid protein production in cells and methods of inhibiting cell death... | 05/30/2006 |
| 7053119 | Methods for identifying and using IKK inhibitors The present invention provides methods and compositions for inhibiting IKK, as well as methods and compositions for identifying compounds with activity as inhibitors of IKK, and methods and compositions for the treatment of diseases and/or conditions wherein IKK is ... | 05/30/2006 |
| 7049340 | Neuroprotective and retinoprotective ophthalmologic drugs The invention concerns a neuroprotective and retinoprotective medicine, whereof the active principle is selected among a group of compounds consisting of ramipril, ramiprilat or any other ramiprilat derivative capable of releasing it in the organism whereto it is ad... | 05/23/2006 |
| RE39096 | Treatment of skin disorders An effective treatment for skin disorders characterized by abnormal skin cell behavior, including a pharmaceutically effective amount of Halofuginone. Skin disorders which can be treated include keloids, hypertrophic scars, psoriasis, acne, seborrhea and alopecia. H... | 05/16/2006 |
| 7045507 | Substituted tetracycline compounds as synergistic antifungal agents Methods and compositions for treating for the synergistic treatment of fungal associated disorders are discussed. ... | 05/16/2006 |
| 7045550 | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy Polyamine effectors are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more polyamine effectors formulated fo... | 05/16/2006 |
| 7030132 | Method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs A method for increasing the systemic exposure of cells selected from tumor cells and normal cells to an orally administered pharmaceutically active compound, wherein a bioenhancer comprising an inhibitor of BCRP is orally administered concomitantly with said orally ... | 04/18/2006 |
| RE39055 | Hepatoselective pharmaceutical actives The invention provides an analogue of a pharmaceutical active whose molecular weight is less than 25,000 Daltons, the analogue comprising a pharmaceutical active whose molecular weight is less than 25,000 Daltons covalently linked to a pendant molecular group wherei... | 04/04/2006 |
| 7022737 | Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses Mammals are treated for infections or for conditions associated with pathologically proliferating mammalian cell growth by administration of a manipulator of nitrosative stress to selectively kill or reduce the growth of the microbes or helminths causing the infecti... | 04/04/2006 |
| 7022700 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines Compounds according to formula I: wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered to increase neutrophil levels in mammels. ... | 04/04/2006 |
| 7005443 | 5-Hydroxy indazole derivatives for treating glaucoma 3-(2-aminoethyl)-1H-indazol-5-ols useful for treating elevated intraocular pressure and glaucoma are disclosed. ... | 02/28/2006 |
| RE38984 | Antifungal combination therapy There is described antifungal combination therapy comprising the use of known antifungal agents such as the azoles or polyenes in combination with a pneumocandin derivative antifungal agent. More particularly, the invention relates to antifungal combination therapy ... | 02/14/2006 |
| 6995150 | Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol Androst-5-ene-3β,17β diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, and for conditions which respond well to DHEA treatment, but where a higher ratio of est... | 02/07/2006 |
| 6987108 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at le... | 01/17/2006 |
| 6984655 | Photodynamic therapy for selectively closing neovasa in eyeground tissue A method is provided for selectively occluding neovascular vessels formed in the ocular fundus of an eye, which includes intravenously administering a mono-L-aspartyl chlorin compound to a patient; subsequently estimating an appropriate time point when the mono-L-as... | 01/10/2006 |
| 6982285 | Control of parasites attached to skin of fish A method of successfully controlling sea lice in commercial fish farming, in an efficient and environmentally friendly way, with the compounds named in claim 1, preferably by injection, and a method of automating this type of control, are described. ... | 01/03/2006 |
| 6967204 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors This invention is directed to a method of treating insulin resistance syndrome (IRS), hypertension and/or type 2 diabetes in a mammal comprising administering to said mammal a cGMP PDE9 inhibitor or a pharmaceutical composition thereof. This invention is also direct... | 11/22/2005 |
| 6964955 | Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol Androst-5-ene-3β,17βdiol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, and for conditions which respond well to DHEA treatment, but where a higher ratio of estr... | 11/15/2005 |
| 6956044 | Compositions and methods for treatment of epilepsy A method of treating a mammal with an epileptic condition, comprising: administering to said mammal a pharmaceutical composition containing an effective amount of an N-phenyl substituted 2-pyridone compound and/or pharmaceutically acceptable salts thereof. ... | 10/18/2005 |
| 6949555 | Use of organic compounds The invention relates to the use of a hypolipidemic agent or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or delay of the progression to overt diabetes, especially type 2, prevention or reduction of microvascular ... | 09/27/2005 |
| 6949529 | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof The present invention provides therapeutic compositions containing lysophosphatidic acids, methods for making the compositions, and methods of use thereof. ... | 09/27/2005 |
| 6943267 | Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases Compounds of the general formula wherein R is selected from the group consisting essentially of hydrogen, methyl, ethyl, phenyl, a carboxyl, or naphthyl substituted or a carbonyl substituted, alkyl of from 3 to 20 carb... | 09/13/2005 |
| 6919350 | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds A method of reducing, treating or preventing drug-mediated respiratory depression, muscle rigidity, or nausea/vomiting in an animal, incident to the administration to said animal of a mixed delta/mu opioid agonist or a respiratory depression-mediating drug, comprisi... | 07/19/2005 |
